| Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech) T Sumi, Y Nagahisa, K Matsuura, M Sekikawa, Y Yamada, H Nakata, ... Thoracic Cancer 12 (22), 3072-3075, 2021 | 7 | 2021 |
| Successful management of severe bronchial asthma exacerbated by Anti‐PD‐L1 treatment: A report of two cases T Sumi, Y Nagahisa, K Matsuura, M Sekikawa, Y Yamada, H Nakata, ... Respirology Case Reports 9 (11), e0868, 2021 | 7 | 2021 |
| Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer T Sumi, Y Koshshino, M Sekikawa, Y Nagahisa, K Matsuura, N Shijubou, ... Investigational New Drugs 40 (6), 1298-1305, 2022 | 4 | 2022 |
| Pseudocirrhosis due to liver metastasis from lung adenocarcinoma N Shijubou, T Sumi, Y Keira, H Shiraishi, Y Nagahisa, K Matsuura, ... Thoracic Cancer 12 (17), 2407-2410, 2021 | 4 | 2021 |
| Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression Y Ikezawa, H Mizugaki, R Morita, K Tateishi, K Yokoo, T Sumi, H Kikuchi, ... Cancer Science 113 (6), 2109-2117, 2022 | 2 | 2022 |
| Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing K Wakuda, M Morita, M Sekikawa, N Morikawa, K Miura, K Doshita, Y Iida, ... International Journal of Clinical Oncology 29 (2), 96-102, 2024 | 1 | 2024 |
| Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer T Sumi, M Sekikawa, Y Nagahisa, K Matsuura, N Shijubou, K Kamada, ... Investigational New Drugs 40 (6), 1315-1321, 2022 | 1 | 2022 |
| Delayed local reaction at a previous injection site reaction with dupilumab T Sumi, Y Nagahisa, K Matsuura, M Sekikawa, Y Yamada, H Nakata, ... Respirology Case Reports 9 (10), 2021 | 1 | 2021 |
| The efficacy and safety of anamorelin among patients with diabetes K Ando, T Naito, S Hamauchi, K Miura, Y Nishibori, A Tonsho, S Matsuda, ... International Journal of Clinical Oncology, 1-7, 2024 | | 2024 |
| Exploring the Relationship Between Anorexia and Therapeutic Efficacy in Advanced Lung Cancer Treatment: A Retrospective Study K Doshita, T Naito, S Matsuda, M Morita, M Sekikawa, K Miura, H Kodama, ... | | 2024 |
| Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small … Y Iida, K Wakuda, T Kawata, M Morita, M Sekikawa, K Doshita, M Yabe, ... Thoracic Cancer, 2024 | | 2024 |
| Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer M Sekikawa, H Murakami, M Morita, K Doshita, K Miura, H Kodama, ... Thoracic Cancer 14 (35), 3475-3482, 2023 | | 2023 |
| MO1-3 Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001 secondary report) K Tateishi, H Mizugaki, Y Ikezawa, R Morita, K Yokoo, T Sumi, H Kikuchi, ... Annals of Oncology 34, S1394, 2023 | | 2023 |
| Prognostic impact of postoperative recurrence in patients with epidermal growth factor receptor-positive non-small cell lung cancer. M Morita, A Ono, M Sekikawa, K Doshita, K Miura, H Kodama, M Yabe, ... | | 2023 |
| 335P Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001) H Yokouchi, H Mizugaki, Y Ikezawa, R Morita, K Tateishi, K Yokoo, T Sumi, ... Annals of Oncology 33, S1574, 2022 | | 2022 |
| Association of tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab therapy for non-small cell lung cancer T Sumi, M Sekikawa, Y Nagahisa, K Matsuura, N Shijubou, K Kamada, ... | | 2022 |
| P29-4 Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001) Y Kitamura, H Mizugaki, Y Ikezawa, R Morita, K Tateishi, K Yokoo, T Sumi, ... Annals of Oncology 33, S524, 2022 | | 2022 |
| Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report K Takeda, T Sumi, Y Nagahisa, K Matsuura, M Sekikawa, H Watanabe, ... Allergy, Asthma & Clinical Immunology 18 (1), 35, 2022 | | 2022 |
| P16. 05 Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC M Kobayashi, H Mizugaki, Y Ikezawa, R Morita, K Tateishi, K Yokoo, ... Journal of Thoracic Oncology 16 (10), S1017, 2021 | | 2021 |
| 1306P Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001) A Nakamura, H Mizugaki, Y Ikezawa, R Morita, K Tateishi, K Yokoo, ... Annals of Oncology 32, S1008, 2021 | | 2021 |
